ALX Oncology Holdings Inc. (ALXO): Price and Financial Metrics
ALXO Price/Volume Stats
| Current price | $7.94 | 52-week high | $15.39 |
| Prev. close | $8.22 | 52-week low | $4.23 |
| Day low | $7.86 | Volume | 136,405 |
| Day high | $8.22 | Avg. volume | 263,965 |
| 50-day MA | $5.97 | Dividend yield | N/A |
| 200-day MA | $8.98 | Market Cap | 324.50M |
ALXO Stock Price Chart Interactive Chart >
ALX Oncology Holdings Inc. (ALXO) Company Bio
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia on April 1, 2020 and is headquartered in Burlingame, CA.
Latest ALXO News From Around the Web
Below are the latest news stories about ALX ONCOLOGY HOLDINGS INC that investors may wish to consider to help them evaluate ALXO as an investment opportunity.
ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational HighlightsSOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarter ended March 31, 2023 and provided clinical development and operational highlights. “In the first quarter of 2023, we continued to make significant progress in advancing our lead program, evorpacept, through new collabora |
ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian CancerSOUTH SAN FRANCISCO, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced the initiation of a Phase 2 investigator-sponsored trial of evorpacept, a next generation CD47 blocker, in combination with liposomal doxorubicin and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with recurrent platinum-resistant ovarian c |
ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple MyelomaSOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced it has entered into a clinical trial collaboration and supply agreement with Sanofi to evaluate the combination of evorpacept, a next generation CD47 blocker, and SARCLISA (isatuximab-irfc), Sanofi’s monoclonal antibody that targets a specific epitope on th |
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $40 (or More), Says Piper SandlerBull or bear market, no investment is a sure thing. Especially in the current financial environment, which remains riddled with uncertainty, finding compelling plays can be challenging for even the most seasoned market watchers. However, this is not to say that investment opportunities with stand-out growth prospects can’t be found. For the more risk-tolerant investor, penny stocks, or tickers trading for less than $5 per share, can be an enticing option. The appeal is clear; the bargain price t |
ALX Oncology and Quantum Leap Healthcare CollaborativeTM Announce First Patient Dosed in the I-SPY-P1 TRIAL in Breast CancerALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announced that the first patient has been dosed in the I-SPY-P1-TRIAL for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. Sponsored by Quantum Leap, this Phase 1 (open-label), multi-center study arm will investigate evor |
ALXO Price Returns
| 1-mo | 21.78% |
| 3-mo | 47.31% |
| 6-mo | -26.14% |
| 1-year | -0.50% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -29.55% |
| 2022 | -47.56% |
| 2021 | -75.07% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...